5-amino-4-cyano-2-methyl-2H-1,2,3-triazole | 28539-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: 5-amino-4-cyano-2-methyl-2H-1,2,3-triazole
• 英文别名: 5-amino-2-methyl-2H-[1,2,3]triazole-4-carbonitrile；4-amino-2-methyl-1,2,3-triazole-5-carbonitrile；4-Amino-2-methyl-1,2,3-triazol-5-carbonitril；2-Methyl-4-cyano-5-amino-1,2,3-triazol；5-amino-2-methyltriazole-4-carbonitrile
• CAS: 28539-27-7
• 化学式: C₄H₅N₅
• mdl: MFCD19203933
• 分子量: 123.117
• InChiKey: KPKZSKHGNDKNRV-UHFFFAOYSA-N

物化性质

• 沸点：
  388.5±52.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-amino-4-cyano-2-methyl-2H-1,2,3-triazole 、 2,5-二氯硝基苯 在 sodium hydride 作用下， 生成 5-(4-Chloro-2-nitroanilino)-2-methyltriazole-4-carbonitrile
  参考文献：
  名称：

  [1,2,3]三唑并[4,5-b] [1,5]-，咪唑并[4,5-b] [1,5]-和吡啶基[2，]的合成和药理学评估3-b] [1,5]苯并二氮杂.。具有抗精神病药活性的10-Piperazinyl-4H-1,2,3-三唑并[4,5-b] [1,5]苯并二氮杂s。

  摘要：

  [1,2,3]三唑并[4,5-b] [1,5]-，咪唑并[4,5-b] [1,5]-和吡啶并[2,3-b] [描述了1，5]苯并二氮杂pine。化合物的抗多巴胺能和抗胆碱能活性已通过各自的体外[3H]哌隆和[3H] QNB受体结合试验进行了检查。就其在小鼠中产生体温过低和僵直的能力以及在大鼠中产生的条件回避反应而言，已进一步评估了其抗精神病药的潜力。只有三唑并苯并二氮杂series系列化合物显示出抗精神病药的潜力。咪唑基和吡啶基苯并二氮杂pine系列缺乏活性表明，杂芳烃部分的碱性可能决定活性。

  DOI：

  10.1021/jm00130a025

文献信息

• Benzodiazepine compounds and their use as pharmaceuticals
  申请人：Lilly House

  公开号：US04431589A1

  公开（公告）日：1984-02-14

  These are described compounds of formula (I) ##STR1## or an acid addition salt thereof; in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, halogen, C.sub.1-4 haloalkyl, nitro, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio or phenylsulphonyl; in which R.sup.5 is a group of the formula ##STR2## where R.sup.7 is hydrogen or C.sub.1-6 alkyl, R.sup.8 is hydrogen or C.sub.1-4 alkyl and n is 0 or 1, provided that when R.sup.7 is hydrogen n is 0; and in which R.sup.6 is attached to the 1, 2 or 3 position of the triazole ring and is hydrogen, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl C.sub.1-4 alkyl, phenyl, benzyl or acyl. These compounds are pharmaceutically active and are especially useful in the treatment of disorders of the central nervous system. They are prepared by reacting an amine of formula R.sup.5 H with a triazolobenzodiazepine intermediate appropriately substituted at the 10-position or by ring-closing the appropriate anilinotriazole.

  这些化合物的式子为(I) ##STR1## 或其酸加成盐；其中R.sup.1、R.sup.2、R.sup.3和R.sup.4独立地代表氢、C.sub.1-4烷基、C.sub.2-4烯基、卤素、C.sub.1-4卤代烷基、硝基、C.sub.1-4烷氧基、C.sub.1-4卤代烷氧基、C.sub.1-4烷硫基或苯基磺酰基；其中R.sup.5是式子##STR2## 的基团，其中R.sup.7是氢或C.sub.1-6烷基，R.sup.8是氢或C.sub.1-4烷基，n为0或1，当R.sup.7为氢时，n为0；其中R.sup.6连接到三唑环的1、2或3位，是氢、C.sub.1-10烷基、C.sub.3-7环烷基、C.sub.3-7环烷基C.sub.1-4烷基、苯基、苄基或酰基。这些化合物具有药理活性，特别适用于治疗中枢神经系统疾病。它们是通过将式子为R.sup.5 H的胺与适当取代10位的三唑苯并二氮平中间体反应或通过合成适当的苯胺三唑并环来制备的。
• Triazolobenzodiazepine derivatives
  申请人：Lilly Industries Limited

  公开号：US04492699A1

  公开（公告）日：1985-01-08

  These are described compounds of formula (I) ##STR1## or an acid addition salt thereof; in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, halogen, C.sub.1-4 haloalkyl, nitro, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio or phenylsulphonyl; in which R.sup.5 is a group of the formula ##STR2## where R.sup.7 is hydrogen or C.sub.1-6 alkyl, R.sup.8 is hydrogen or C.sub.1-4 alkyl and n is 0 or 1, provided that when R.sup.7 is hydrogen n is 0; and in which R.sup.6 is attached to the 1, 2 or 3 position of the triazole ring and is hydrogen, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl C.sub.1-4 alkyl, phenyl, benzyl or acyl. These compounds are pharmaceutically active and are especially useful in the treatment of disorders of the central nervous system. They are prepared by reacting an amine of formula R.sup.5 H with a triazolobenzodiazepine intermediate appropriately substituted at the 10-position or by ring-closing the appropriate anilinotriazole.

  这是化合物的描述式(I) ##STR1## 或其酸加成盐；其中R.sup.1，R.sup.2，R.sup.3和R.sup.4分别表示氢，C.sub.1-4烷基，C.sub.2-4烯基，卤素，C.sub.1-4卤代烷基，硝基，C.sub.1-4烷氧基，C.sub.1-4卤代烷氧基，C.sub.1-4烷硫基或苯基磺酰基；其中R.sup.5是以下式的基团##STR2## 其中R.sup.7是氢或C.sub.1-6烷基，R.sup.8是氢或C.sub.1-4烷基，n为0或1，但当R.sup.7是氢时，n为0；其中R.sup.6连接到三唑环的1、2或3位，是氢，C.sub.1-10烷基，C.sub.3-7环烷基，C.sub.3-7环烷基C.sub.1-4烷基，苯基，苄基或酰基。这些化合物具有药理活性，特别适用于治疗中枢神经系统疾病。它们通过将式R.sup.5 H的胺与适当取代10位的三唑苯二氮平中间体反应或环合适当的苯胺三唑制备。
• CHAKRABARTI, J. K.;HOTTEN, T. M.;STEGGLES, D. J.
  作者：CHAKRABARTI, J. K.、HOTTEN, T. M.、STEGGLES, D. J.

  DOI：——

  日期：——
• ALBERT A., J. CHEM. SOC. PERKIN TRANS. <JCPK-BH>, 1975, PART 1, NO 4, 345-349
  作者：ALBERT A.

  DOI：——

  日期：——
• ALBERT A.; LIN C. J., J. CHEM. SOC. PERKIN TRANS., PART 1 <JCPK-BH>, 1977, NO 2, 210-213
  作者：ALBERT A.、 LIN C. J.

  DOI：——

  日期：——